Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANALOG DEVICES INCADI · Entity 591 | Director | March 11, 2026 | March 12, 2026 |
| NEOGEN CORPNEOG · Entity 4338 | Director | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANALOG DEVICES INC
Report date March 11, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Comm Stock - $.16-2/3 valueSEC Table I · non-derivative | Direct | 2,325 |
Reported balance
After 2026-03-11 transaction · row 1
1 source rowRow 1 · 2026-03-11 · Grant · Acquired 747 · Balance 2,325 F1: Annual grant to non-employee director of Restricted Stock Units (RSUs) that vest 100% on the earlier of March 11, 2027 or the date of the Company's next Annual Meeting of Shareholders. Upon the vesting date, each vested RSU shall automatically convert into one (1) share of common stock of the Company. |
| Comm Stock - $.16-2/3 valueSEC Table I · non-derivative | IndirectBy Spouse | 50 |
Reported balance
Holding disclosure · report date 2026-03-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 50 |
Filing footnotes · ownership attribution and instrument terms
F1: Annual grant to non-employee director of Restricted Stock Units (RSUs) that vest 100% on the earlier of March 11, 2027 or the date of the Company's next Annual Meeting of Shareholders. Upon the vesting date, each vested RSU shall automatically convert into one (1) share of common stock of the Company.
NEOGEN CORP
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 11,834 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 9,804 · Balance 11,834 F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants |
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.24 · Expires 2036-10-01 | Direct | 20,558 |
Reported balance
After 2026-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-01 · Grant · Acquired 20,558 · Balance 20,558 F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants |
Filing footnotes · ownership attribution and instrument terms
F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date February 28, 2025 · Filed March 05, 2025
Section 16 reporting ended · disclosed 2025-03-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 74,381 |
Ending reported balance
After 2025-03-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-28 · Tax withholding · Disposed 7,313 · Balance 75,330 Row 2 · 2025-03-03 · Sale · Disposed 949 · Balance 74,381 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 21:12 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock (Right to Buy) · Derivative | 20,558 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0000711377-26-000027 · primary_doc.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,558 Underlying: Common Stock · 20,558 shares Expires 2036-10-01 F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 21:12 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantRestricted Stock Units | 9,804 | $12.24 | $120,000.96 |
DisclosureSEC source: 0000711377-26-000027 · primary_doc.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,834 F1 · shares: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| March 11, 2026 Filed Mar 12, 2026 20:19 UTC | ANALOG DEVICES INC ADI · Entity 591 | GrantComm Stock - $.16-2/3 value | 747 | $0.00 | $0.00 |
DisclosureSEC source: 0001778070-26-000002 · wk-form4_1773346748.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,325 F1 · shares: Annual grant to non-employee director of Restricted Stock Units (RSUs) that vest 100% on the earlier of March 11, 2027 or the date of the Company's next Annual Meeting of Shareholders. Upon the vesting date, each vested RSU shall automatically convert into one (1) share of common stock of the Company. Read SEC document |
| October 23, 2025 Filed Oct 27, 2025 20:18 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock (Right to Buy) · Derivative | 50,814 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0000711377-25-000055 · primary_doc.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,814 Underlying: Common Stock · 50,814 shares Expires 2035-10-23 F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| October 23, 2025 Filed Oct 27, 2025 20:18 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock | 19,769 | $6.07 | $119,997.83 |
DisclosureSEC source: 0000711377-25-000055 · primary_doc.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,769 F1 · shares: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:08 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock (Right to Buy) · Derivative | 16,303 | $0.00 Strike: $5.69 | $0.00 |
DisclosureSEC source: 0000711377-25-000022 · primary_doc.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,303 Underlying: Common Stock · 16,303 shares Expires 2032-06-02 F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:08 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock | 6,090 | $5.69 | $34,652.10 |
DisclosureSEC source: 0000711377-25-000022 · primary_doc.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,090 F1 · shares: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:50 UTC | ANALOG DEVICES INC ADI · Entity 591 | GrantComm Stock - $.16-2/3 value | 1,160 | $0.00 | $0.00 |
DisclosureSEC source: 0000006281-25-000058 · wk-form4_1741985449.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,596 F1 · shares: Annual grant to non-employee director of Restricted Stock Units (RSUs) that vest 100% on the earlier of March 12, 2026 or the date of the Company's next Annual Meeting of Shareholders. Upon the vesting date, each vested RSU shall automatically convert into one (1) share of common stock of the Company. F2 · balance_after: Includes 185 shares of common stock received from RSUs that vested on March 12, 2025 and were previously reported in Table II of Form 4. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 949 | $138.17 | $131,123.33 |
DisclosureSEC source: 0001415889-25-006798 · form4-03052025_010318.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · RETIRED EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,381 Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,313 | $135.87 | $993,617.31 |
DisclosureSEC source: 0001415889-25-006798 · form4-03052025_010318.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · RETIRED EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,330 Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 45,730 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005920 · form4-02272025_110232.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,730 Underlying: Common Shares · 45,730 shares Expires 2035-02-24 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,243 on February 25, 2026, 15,243 on February 25, 2027, and 15,244 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 12,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005920 · form4-02272025_110232.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,643 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:44 UTC | ANALOG DEVICES INC ADI · Entity 591 | GrantRestricted Stock Unit · Derivative | 185 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000006281-25-000027 · wk-form4_1740001435.xml · derivative · entry 1 Wainer Andrea F · CIK 0001778070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185 Underlying: Comm Stock - $.16-2/3 value · 185 shares Expires not disclosed F1 · derivative.exercise_date: This RSU vests 100% on the earlier of the date of the Company's 2025 Annual Meeting of Shareholders or March 13, 2025. Upon the vesting date, each vested RSU shall automatically convert into one (1) share of common stock of the Company. F1 · derivative.expiration_date: This RSU vests 100% on the earlier of the date of the Company's 2025 Annual Meeting of Shareholders or March 13, 2025. Upon the vesting date, each vested RSU shall automatically convert into one (1) share of common stock of the Company. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 00:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,339 | $120.05 | $1,001,096.95 |
DisclosureSEC source: 0001415889-24-006422 · form4-03052024_120352.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,365 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 12,500 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001415889-24-005576 · form4-02272024_110219.xml · derivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,449 Underlying: Common Shares · 12,500 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 12,500 | $120.00 | $1,500,000.00 |
DisclosureSEC source: 0001415889-24-005576 · form4-02272024_110219.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,704 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 12,500 | $59.94 | $749,250.00 |
DisclosureSEC source: 0001415889-24-005576 · form4-02272024_110219.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 51,397 | $0.00 Strike: $116.98 | $0.00 |
DisclosureSEC source: 0001415889-24-005110 · form4-02232024_100243.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,397 Underlying: Common Shares · 51,397 shares Expires 2034-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,132 on February 21, 2025, 17,132 on February 21, 2026, and 17,133 on February 21, 2027. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,677 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005110 · form4-02232024_100243.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,704 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 17,500 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001415889-24-002080 · form4-01312024_100152.xml · derivative · entry 6 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,949 Underlying: Common Shares · 17,500 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001415889-24-002080 · form4-01312024_100152.xml · derivative · entry 5 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,271 Underlying: Common Shares · 25,000 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 17,500 | $112.50 | $1,968,750.00 |
DisclosureSEC source: 0001415889-24-002080 · form4-01312024_100152.xml · nonDerivative · entry 4 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,027 Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 17,500 | $59.94 | $1,048,950.00 |
DisclosureSEC source: 0001415889-24-002080 · form4-01312024_100152.xml · nonDerivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 25,000 | $112.50 | $2,812,500.00 |
DisclosureSEC source: 0001415889-24-002080 · form4-01312024_100152.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,027 Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 25,000 | $44.40 | $1,110,000.00 |
DisclosureSEC source: 0001415889-24-002080 · form4-01312024_100152.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001415889-23-016642 · form4-12182023_101216.xml · derivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,271 Underlying: Common Shares · 15,000 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 15,000 | $108.00 | $1,620,000.00 |
DisclosureSEC source: 0001415889-23-016642 · form4-12182023_101216.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,027 Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 15,000 | $44.40 | $666,000.00 |
DisclosureSEC source: 0001415889-23-016642 · form4-12182023_101216.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-23-012074 · form4-08102023_100835.xml · derivative · entry 8 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 16 | $107.42 | $1,718.72 |
DisclosureSEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 7 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,027 Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 272 | $105.43 | $28,676.96 |
DisclosureSEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 6 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,043 Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,112 | $105.00 | $536,760.00 |
DisclosureSEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 5 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,315 Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 15 | $107.42 | $1,611.30 |
DisclosureSEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 4 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,427 Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 244 | $105.43 | $25,724.92 |
DisclosureSEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,442 Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,741 | $105.00 | $497,805.00 |
DisclosureSEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,686 Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,000 | $38.40 | $192,000.00 |
DisclosureSEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2023 Filed May 3, 2023 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 8,226 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007254 · form4-05032023_110540.xml · derivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,226 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 02, 2023 Filed May 3, 2023 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,226 | $110.56 | $909,472.32 |
DisclosureSEC source: 0001415889-23-007254 · form4-05032023_110540.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,427 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.5501 to $110.562, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 02, 2023 Filed May 3, 2023 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 8,226 | $47.00 | $386,622.00 |
DisclosureSEC source: 0001415889-23-007254 · form4-05032023_110540.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 00:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 679 | $100.70 | $68,375.30 |
DisclosureSEC source: 0001415889-23-003921 · form4-03032023_120354.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,427 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,531 | $99.77 | $751,367.87 |
DisclosureSEC source: 0001415889-23-003921 · form4-03032023_120354.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,106 Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 71,907 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003068 · form4-02232023_120224.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,907 Underlying: Common Shares · 71,907 shares Expires 2033-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,969 on February 17, 2024, 23,969 on February 17, 2025, and 23,969 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 18,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003068 · form4-02232023_120224.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,637 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,768 | $117.51 | $207,757.68 |
DisclosureSEC source: 0001415889-22-006224 · form4-06072022_020612.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,404 Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 01:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 456 | $118.13 | $53,866.37 |
DisclosureSEC source: 0001415889-22-002201 · form4-03022022_050341.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,172 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,126 | $122.41 | $749,883.66 |
DisclosureSEC source: 0001415889-22-002201 · form4-03022022_050341.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,628 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 88,418 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001747 · form4-02232022_050203.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,418 Underlying: Common Shares · 88,418 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,472 on February 18, 2023, 29,473 on February 18, 2024, and 29,473 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 18,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001747 · form4-02232022_050203.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,754 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,000 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-006265 · form4-12282021_021257.xml · derivative · entry 8 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,226 Underlying: Common Shares · 3,000 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,000 | $142.50 | $427,500.00 |
DisclosureSEC source: 0001415889-21-006265 · form4-12282021_021257.xml · nonDerivative · entry 5 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.